De Quervain Tenosynovitis
Conditions
Brief summary
De Quervain's tenosynovitis (DQT) was originally identified by Swiss surgeon Fritz de Quervain in 1895. It is a condition involving the entrapment of tendons within the first dorsal compartment of the wrist. In DQT, the sheaths surrounding the abductor pollicis longus (APL) and extensor pollicis brevis tendons thicken as they pass through a fibro-osseous tunnel near the radial styloid of the distal wrist. This thickening leads to pain, which worsens with thumb movements and radial or ulnar deviation of the wrist. Traditional treatment methods, such as corticosteroid injections and physical therapy, often provide only temporary relief and may not address the underlying inflammation effectively. Intralesional platelet rich plasma (PRP) therapy has emerged as a promising alternative, utilizing the patient's own growth factors and cytokines to promote healing and reduce inflammation. By investigating the efficacy of intralesional PRP in patients with DQT, this research aims to provide evidence for a minimally invasive treatment option that could enhance recovery times, reduce pain, and improve functional outcomes.
Interventions
OTHERPlatelet Rich Plasma
Under aseptic measures, a phlebotomist obtained the blood in vacutainers. Vacutainers was centrifuged and middle zone containing platelet rich plasma was aspirated in a 5 ml disposable syringe. The patient received intralesional injection
Sponsors
Muhammad Aamir Latif
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Intervention model description
Quasi-experimental study
Eligibility
Sex/Gender
ALL
Age
18 Years to 60 Years
Healthy volunteers
No
Inclusion criteria
* Either gender, * Aged between 18 and 60 years * Presenting with de quervain's tenosynovitis
Exclusion criteria
* Previous surgery or intervention forde quervain's tenosynovitis * Local skin infection or osteomyelitis * Pregnant or lactating mothers
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| VAS Pain Score | 3-week | The patients were evaluated three weeks after treatment for efficacy. Efficacy was labeled as VAS pain score \< 3 after 3 weeks of intralesional PRP injection. |
Countries
Pakistan
Outcome results
None listed